公开(公告)号：WO2008005368A3

公开(公告)日：2008-01-10

申请号：PCT/US2007/015192

申请日：2007-06-29

Applicant: ABBOTT LABORATORIES ,  BETSCHMANN, Patrick ,  CARROLL, William A. ,  ERICSSON, Anna M. ,  FIX-STENZEL, Shannon R. ,  FRIEDMAN, Michael ,  HIRST, Gavin C. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin ,  PEREZ-MEDRANO, Arturo ,  MORYTKO, Michael J. ,  RAFFERTY, Paul ,  CHEN, Haipeng

Inventor： BETSCHMANN, Patrick ,  CARROLL, William A. ,  ERICSSON, Anna M. ,  FIX-STENZEL, Shannon R. ,  FRIEDMAN, Michael ,  HIRST, Gavin C. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin ,  PEREZ-MEDRANO, Arturo ,  MORYTKO, Michael J. ,  RAFFERTY, Paul ,  CHEN, Haipeng

IPC: A61K31/497 ,  C07D401/12 ,  C07D403/12

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.

公开(公告)号：WO2009042193A1

公开(公告)日：2009-04-02

申请号：PCT/US2008/011146

申请日：2008-09-25

Applicant: ABBOTT LABORATORIES ,  GEORGE, Dawn, M. ,  WANG, Lu ,  LI, Biqin ,  ERICSSON, Anna, M. ,  ANSELL, Graham, K.

Inventor： GEORGE, Dawn, M. ,  WANG, Lu ,  LI, Biqin ,  ERICSSON, Anna, M. ,  ANSELL, Graham, K.

IPC: A01N37/18 ,  A61K31/165

CPC classification number: C07D471/04 ,  C07D211/14 ,  C07D295/185 ,  C07D309/14 ,  C07D405/12

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的盐，其前药，其生物活性代谢物，其异构体或其立体异构体，其中变量如本文所定义。 式（I）的化合物可用作趋化因子受体拮抗剂，因此可用于治疗某些病症和疾病，特别是炎性病症和疾病以及增殖性疾病和病症，例如类风湿性关节炎，骨关节炎，多发性硬化和哮喘。

公开(公告)号：WO2008154241A1

公开(公告)日：2008-12-18

申请号：PCT/US2008/065727

申请日：2008-06-04

Applicant: ABBOTT LABORATORIES ,  AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric T ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

Inventor： AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric T ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R 1 , R 2 , R 3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶如糖原合酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），AKT，PAK4 ，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。

公开(公告)号：WO2008060621A3

公开(公告)日：2008-05-22

申请号：PCT/US2007/024076

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES ,  GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

公开(公告)号：WO2007117465A2

公开(公告)日：2007-10-18

申请号：PCT/US2007/008307

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES ,  ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。

公开(公告)号：WO2005111003A1

公开(公告)日：2005-11-24

申请号：PCT/US2005/014641

申请日：2005-04-28

Applicant: ABBOTT LABORATORIES ,  LI, Tongmei ,  CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  FLORJANCIC, Alan, S. ,  NELSON, Derek, W. ,  PEDDI, Sridhar ,  BUNNELLE, Eric, M. ,  HIRST, Gavin, C. ,  LI, Biqin

Inventor： CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  FLORJANCIC, Alan, S. ,  NELSON, Derek, W. ,  PEDDI, Sridhar ,  BUNNELLE, Eric, M. ,  HIRST, Gavin, C. ,  LI, Biqin

IPC: C07D257/06

CPC classification number: C07D487/04 ,  C07D257/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08

Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.

Abstract translation: 公开了具有式（I）或式（II）的化合物作为P2X7拮抗剂，其中A，B，C，Y，Y，Z，m，v，R 1，R 2，R 3， R 4和R 5如说明书中所定义。 还公开了用于治疗由P2X7调节的疾病或病症的方法和组合物。

公开(公告)号：EP2203051A1

公开(公告)日：2010-07-07

申请号：EP08834489.0

申请日：2008-09-25

Applicant: Abbott Laboratories

Inventor： GEORGE, Dawn, M. ,  WANG, Lu ,  LI, Biqin ,  ERICSSON, Anna, M. ,  ANSELL, Graham, K.

IPC: A01N37/18 ,  A61K31/165

CPC classification number: C07D471/04 ,  C07D211/14 ,  C07D295/185 ,  C07D309/14 ,  C07D405/12

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.

公开(公告)号：EP2001480A2

公开(公告)日：2008-12-17

申请号：EP07754773.5

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新化合物或其式（I）的药用盐，前药和生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。

公开(公告)号：EP2167491A1

公开(公告)日：2010-03-31

申请号：EP08770094.4

申请日：2008-06-04

Applicant: Abbott Laboratories ,  Abbott GmbH & Co. KG

Inventor： AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric F. ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

公开(公告)号：EP2099454A2

公开(公告)日：2009-09-16

申请号：EP07867491.8

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

CPC classification number: A61K31/454 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4747 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D207/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D487/14

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.